Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: Association with dynamic contrast-enhanced MR imaging with computer-aided evaluation

Radiology

Volumn 268, Issue 3, 2013, Pages 662-672

  Yi, Ann ^a   Cho, Nariya ^a   Im, Seock Ah ^a   Chang, Jung Min ^a   Kim, Seung Ja ^a   Moon, Hyeung Gon ^a   Han, Wonshik ^a   Park, In Ae ^a   Noh, Dong Young ^a   Moon, Woo Kyung ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER STAGING; COMPUTER AIDED DESIGN; CONTRAST ENHANCEMENT; DEATH; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883205694     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13121801     Document Type: Article

References (31)

1. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26(5): 778-785.
2. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19(22): 4224-4237.
3. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin- based neoadjuvant chemotherapy. J Clin Oncol 1999;17(2): 460-469.
4. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008;26(5): 814-819.
5. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25(28): 4414-4422.
6. Balko JM, Cook RS, Vaught DB, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 2012;18(7): 1052-1059.
7. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - results from ACRIN 6657/I-SPY TRIAL. Radiology 2012;263(3): 663-672.
8. Li SP, Makris A, Beresford MJ, et al. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology 2011;260(1): 68-78.
9. Pickles MD, Manton DJ, Lowry M, Turnbull LW. Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. Eur J Radiol 2009;71(3): 498-505.
10. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14(20): 6580-6589.
11. Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging 2007;26(3): 615-623.
12. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005;184(6): 1774-1781.
13. Williams TC, DeMartini WB, Partridge SC, Peacock S, Lehman CD. Breast MR imaging: computer-aided evaluation program for discriminating benign from malignant lesions. Radiology 2007;244(1): 94-103.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2): 228-247.
15. Fumagalli D, Bedard PL, Nahleh Z, et al. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 2012;13(6):e240-e248.
16. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25(15): 2127-2132.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3): 205-216.
18. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42(8): 1031-1039.
19. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3): 223-232.
20. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146(5): 1029-1039.
21. Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999;211(1): 101-110.
22. Li KL, Henry RG, Wilmes LJ, et al. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med 2007; 58(3): 572-581.
23. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003; 18(4): 467-477.
24. Lee SH, Cho N, Kim SJ, et al. Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol 2008;9(1): 10-18.
25. Calcagno AM, Salcido CD, Gillet JP, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010;102(21): 1637-1652.
26. Lee HE, Kim JH, Kim YJ, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011; 104(11): 1730-1738.
27. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8): 1275-1281.
28. Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007;7:203.
29. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence- free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30(26): 3242-3249.
30. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011;29(6): 660-666.
31. Jansen SA, Shimauchi A, Zak L, et al. Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrastenhanced MRI acquisition. AJR Am J Roentgenol 2009;193(3): 832-839.